Vita 34 AG

Vita 34 significantly increases earnings and operating cash flow in the first quarter

Vita 34 returns to growth path in 2023

Vita 34 closes 2023 with significantly better results than expected based on preliminary figures

Vita 34 publishes preliminary figures on the course of business in 2023

Vita 34 downsizes Management Board until further notice

Vita 34 AG: AOC Health GmbH, Acquisition of shares as part of a capital increase

Vita 34 AG: Jakub Julian Baran, buy

Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Vita 34 AG: resolves on cash capital increase under exclusion of subscription rights in the amount of up to 10% of the share capital, commitments from investors

Vita 34 increases revenue and earnings in Q3 2023 and further stabilizes business development

Internal investigation by Vita 34 AG reveals irregularities related to a limited number of biological samples at one of its subsidiaries regarding compliance with medical law requirements

Vita 34 AG: A subsidiary of Vita 34, FamiCordTx, will file a lawsuit against a US licensor

Vita 34 stabilizes business development in the second quarter and noticeably improves earnings

Vita 34 successfully implements price increases in first quarter of 2023 in generally weak market environment

Vita 34 Starts Recruitment for Clinical Trial with CAR-T Drug Candidate

Development of Vita 34 AG in 2022 stressed by weakened consumption power of consumers along with one-off effects

Vita 34 AG publishes outlook for the 2023 financial year

2022 annual result of Vita 34 AG significantly influenced by impairment of goodwill

Vita 34 benefits from increasing normalization in its core business in the third quarter

EQS-DD: Vita 34 AG english

Vita 34 records moderate upward trend in the second quarter

Vita 34 lowers sales and earnings guidance due to IFRS 15 effect and accelerated restructuring measures